Screener
SG&A at other companies
Segments
By segment
Other financials
Where this comes from
Reported directly by Ionis Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:SellingGeneralAndAdministrativeExpense.
The source filing: Ionis Pharmaceuticals’s 10-Q, filed July 29, 2026.
- Filed
- Jul 29, 2026, 5:05 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0000874015-26-000251
| Line item | Three Months Ended / June 30, 2026 | Three Months Ended / June 30, 2025 | Six Months Ended / June 30, 2026 | Six Months Ended / June 30, 2025 |
|---|---|---|---|---|
| Expenses: | ||||
| Cost of sales | 2,739 | 4,151 | 5,721 | 5,614 |
| Research, development and patent | 217,107 | 217,460 | 427,280 | 418,219 |
| Selling, general and administrative | 150,396 | 90,622 | 300,755 | 166,872 |
| Total operating expenses | 370,242 | 312,233 | 733,756 | 590,705 |
| Income (loss) from operations | (102,293) | 139,816 | (219,714) | (7,045) |
| Other income (expense): | ||||
| Investment income | 20,230 | 24,687 | 45,713 | 49,354 |
ITEM 1. FINANCIAL STATEMENTS
FAQ
- What is Ionis Pharmaceuticals's SG&A?
- Ionis Pharmaceuticals (IONS) reported SG&A of $150.4M in Q2 2026.
- How has Ionis Pharmaceuticals's SG&A changed year-over-year?
- Ionis Pharmaceuticals's SG&A increased by 66.0% year-over-year, from $90.62M to $150.4M.
- What is the long-term trend for Ionis Pharmaceuticals's SG&A?
- Over 4 years (2021 to 2025), Ionis Pharmaceuticals's SG&A has grown at a 20.6% compound annual growth rate (CAGR), from $186.35M to $393.87M.
- What does SG&A mean?
- Combined selling expenses (sales force, marketing, distribution) and general & administrative costs (management, legal, accounting, facilities) — the broadest opex category.
Ask your AI about Ionis Pharmaceuticals's sg&a.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude